PGNY today
$36.58+$0.08 (+0.22%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourAscending Triangle
1 hourLeaning Bearish
15 minBearish
5 minLeaning Bullish
Daily trend turns up above $33.06
Key levels
Resistance$40.89
Resistance$38.98
Support$36.36
Support$33.84
Latest news & SEC filings
AnalystJ.P. Morgan kept its Neutral rating on Progyny (PGNY) and raised its price target to $35 from $30.
AnalystLeerink Partners kept its Outperform rating on Progyny (PGNY) with a price target of $38.
AnalystWells Fargo kept its Overweight rating on Progyny (PGNY) and raised its price target to $38 from $37.
AnalystCitizens JMP kept its Market Outperform rating on Progyny (PGNY) and raised its price target to $38 from $33.
AnalystCantor Fitzgerald kept its Overweight rating on Progyny (PGNY) with a price target of $35.
All PGNY news →About Progyny
Progyny provides fertility and family building benefits to employers and their workers. Its offerings include a fertility treatment plan with bundled cycles, an integrated pharmacy benefit, and programs for pregnancy, postpartum, menopause, and parenting. It also offers reimbursement for adoption, surrogacy, and related expenses. The company serves large self-insured employers and operates in the United States and globally.
Based on the company's 10-K filed Feb 27, 2026.
Nasdaq · Healthcare
Progyny, Inc. (PGNY)
What Is the Price Target for PGNY?
SEPT Low Target
$30.00
SEPT Mid Target
$35.00
SEPT High Target
$40.00
Analyst Consensus
$35.00
Is PGNY a Buy or Sell Right Now?
Thesis
- •Revenue growing 10.4% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PGNY.
Start Free Trial →Is PGNY Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$28.49
48
Moat Score
NARROW
5/9
Piotroski Score
10.1
Altman Z-Score
What Is Smart Money Doing with PGNY?
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Livingston Mark S. | officer | Sale | 2,139 | $64K | Nov 4, 2026 |
| Swartz Allison | officer | Buy | 8,160 | - | Nov 2, 2026 |
| Cummings Melissa B | officer | Sale | 1,559 | $43K | Oct 14, 2026 |
| Cummings Melissa B | officer | Sale | 1,879 | $53K | Oct 14, 2026 |
| Swartz Allison | officer | Sale | 3,903 | $102K | Sep 23, 2026 |
| Clapp Geoffrey | officer | Sale | 819 | $22K | Sep 17, 2026 |
| GORDON KEVIN K | director | Buy | 22,000 | $286K | Sep 10, 2026 |
| GORDON KEVIN K | director | Sale | 10,500 | $286K | Sep 10, 2026 |
| GORDON KEVIN K | director | Sale | 11,500 | $321K | Sep 10, 2026 |
| Swartz Allison | officer | Sale | 479 | $13K | Sep 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PGNY Growth Story
Revenue YoY
10.4%
3yr Revenue CAGR
17.9%
EPS Growth YoY
14.04%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for PGNY
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PGNY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:31:45 | $36.58 | 8,313 | $$304K | BUY |
| 21:04:26 | $36.58 | 14,144 | $$517K | BUY |
| 21:00:28 | $36.58 | 1,886 | $$69K | BUY |
| 21:00:28 | $36.58 | 3,402 | $$124K | BUY |
| 20:59:57 | $36.59 | 1,004 | $$37K | MIDPOINT |
5 dark pool trades shown · $$1.1M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Progyny, Inc. (PGNY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PGNY — frequently asked questions
What is PGNY stock price today?
Progyny, Inc. (PGNY) is at $36.58, up 0.22% (+$0.08) at the Nov 12, 2026 close.
Why is PGNY stock moving today?
Latest PGNY news — Nov 9, 2026: J.P. Morgan kept its Neutral rating on Progyny (PGNY) and raised its price target to $35 from $30. · Nov 5, 2026: Leerink Partners kept its Outperform rating on Progyny (PGNY) with a price target of $38.
What is the PGNY price target?
The average analyst price target for PGNY is $35.00, ranging from $30 to $40, based on 9 analysts. Latest: Citizens maintains on Sep 8, 2026.
What do analysts rate PGNY?
Analyst ratings for PGNY: 2 Buy, 12 Hold, 0 Sell — consensus Hold.
Did PGNY beat earnings?
PGNY last reported on Aug 6, 2026: EPS $0.55 vs $0.28 expected — a beat of 96.4%.
What is PGNY's P/E ratio?
PGNY trades at a P/E of 31.6 vs a Healthcare average of 17.7.
Does PGNY pay a dividend?
PGNY does not currently pay a dividend.
What are PGNY support and resistance levels?
Support: $36.36, $33.84, $31.84. Resistance: $38.98, $40.89.
What are insiders doing with PGNY?
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
What is the latest news on PGNY?
Nov 9, 2026: J.P. Morgan kept its Neutral rating on Progyny (PGNY) and raised its price target to $35 from $30. · Nov 5, 2026: Leerink Partners kept its Outperform rating on Progyny (PGNY) with a price target of $38. · Nov 5, 2026: Wells Fargo kept its Overweight rating on Progyny (PGNY) and raised its price target to $38 from $37.